You just read:

Novartis' investigational heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in PARADIGM-HF trial

News provided by

Novartis Pharmaceuticals Canada Inc.

Aug 30, 2014, 12:21 ET